Table 3 Relationship between the incidence of the primary endpoint and the AIP expressed as a categorical variable

 Q1

Reference

Reference

 Q2

1.376 (0.878–2.156)

0.164

1.167 (0.733–1.857)

0.516

 Q3

1.710 (1.109–2.636)

0.015

1.570 (0.995–2.478)

0.053

 Q4

2.265 (1.491–3.440)

< 0.001

2.249 (1.438–3.517)

< 0.001

Age

1.005 (0.991–1.019)

0.472

0.996 (0.980–1.012)

0.642

BMI

0.959 (0.916–1.005)

0.078

0.922 (0.876–0.970)

0.002

Hypertension

1.068 (0.789–1.447)

0.669

1.241 (0.890–1.729)

0.203

Previous MI

1.492 (1.095–2.033)

0.011

0.781 (0.532–1.145)

0.205

Past PCI

1.723 (1.285–2.310)

< 0.001

1.263 (0.734–2.080)

0.425

PAD

2.511 (1.836–3.435)

< 0.001

1.717 (1.192–2.473)

0.004

Cardiac failure

1.951 (1.308–2.909)

0.001

1.165 (0.677–2.004)

0.581

LVEF

0.974 (0.959–0.990)

0.002

0.983 (0.962–1.004)

0.120

SCr

1.013 (1.006–1.021)

0.001

1.010 (1.002–1.019)

0.014

LDL-C

1.078 (0.916–1.269)

0.366

1.028 (0.852–1.239)

0.774

FPG

1.201 (1.132–1.274)

< 0.001

1.156 (1.087–1.230)

< 0.001

 UAP

Reference

Reference

 NSTEMI

0.677 (0.416–1.102)

0.117

0.467 (0.275–0.792)

0.005

 STEMI

1.098 (0.690–1.747)

0.695

0.850 (0.508–1.424)

0.538

 One-vessel disease

Reference

Reference

 Two-vessel disease

1.756 (0.809–3.810)

0.154

1.230 (0.549–2.755)

0.615

 LM/three-vessel disease

3.541 (1.740–7.205)

< 0.001

1.823 (0.858–3.873)

0.118

Restenotic lesions

2.290 (1.658–3.163)

< 0.001

1.667 (0.914–3.040)

0.095

Lesions > 20 mm long

1.984 (1.461–2.695)

< 0.001

1.566 (1.129–2.174)

0.007

DCB use

1.913 (1.228–2.980)

0.004

0.990 (0.571–1.715)

0.970

Complete revascularization

0.467 (0.352–0.619)

< 0.001

0.687 (0.504–0.936)

0.017

Insulin at discharge

1.396 (1.051–1.854)

0.021

1.056 (0.775–1.438)

0.730